Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 6, 2006Journal of Hypertension

The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage

View Full Paper
Ask AI
Bookmark
Share

Key result

The combination of low-dose azelnidipine and olmesartan significantly attenuated ischemic brain area, neurological score, and superoxide production after MCA occlusion in mice.

Why the study?

Does the combination of azelnidipine and olmesartan reduce ischemic brain damage in a mouse model of middle cerebral artery occlusion?

Population

Male C57BL/6J mice and AT1a receptor-deficient mice with focal brain ischemia induced by permanent middle…

Comparison

Azelnidipine, olmesartan, or a combination of… vs Vehicle/control or monotherapy at lower doses

Design

Preclinical

Follow-up

24 hours post-occlusion

Authors

MIMasaru IwaiKumamoto UniversityRCRui ChenWenzhou Medical UniversityAIAyumi IdeMisasa Onsen Hospital

Discussion

Loading...

Member takes

Implication

Hypothesis-generating for CCB-ARB synergy in experimental stroke; should not change practice without clinical trials.

Structured PICO

Does the combination of azelnidipine and olmesartan reduce ischemic brain damage in a mouse model of middle cerebral artery occlusion?

P
Population
Male C57BL/6J mice and AT1a receptor-deficient mice subjected to permanent occlusion of the middle cerebral artery to induce focal cerebral ischemia.
I
Intervention
Azelnidipine (1.0 mg/kg/day for 10 days), olmesartan (3.0 mg/kg/day), or a combination of lower doses (azelnidipine 0.1 mg/kg/day and olmesartan 0.5 mg/kg/day)
C
Comparator
Vehicle/control or monotherapy at lower doses
O
Outcome
Ischemic brain area, neurological score, superoxide production, and cerebral surface blood flow at 24 hours post-occlusionsurrogate

The combination of a calcium-channel blocker and an AT1 receptor blocker synergistically reduces ischemic brain damage and oxidative stress in a mouse model of stroke.

Cite This Study

Iwai et al. (2006) studied Focal brain ischemia. Azelnidipine and olmesartan vs. Single agents or control was evaluated on Ischemic brain area, neurological score, superoxide production, and reduction of cerebral surface blood flow. The combination of low-dose azelnidipine and olmesartan significantly attenuated ischemic brain area, neurological score, and superoxide production after MCA occlusion in mice.

synapsesocial.com/papers/6a8c2b76e066a6a97ec470bbhttps://doi.org/10.1097/01.hjh.0000244952.54738.f6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation2004 · 252 citations
  2. 2Calcium Channel Blocker Azelnidipine Enhances Vascular Protective Effects of AT 1 Receptor Blocker Olmesartan2004 · 76 citations
  3. 3Protection Against Ischemia and Improvement of Cerebral Blood Flow in Genetically Hypertensive Rats by Chronic Pretreatment With an Angiotensin II AT 1 Antagonist2002 · 206 citations
  4. 4Role of AT 2 receptor in the brain in regulation of blood pressure and water intake2003 · 96 citations
  5. 5Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol2002 · 5,435 citations